Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: May 6, 2003
Last updated: June 17, 2012
Last verified: July 2009

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery may kill any tumor cells remaining after surgery.

PURPOSE: This phase II trial is studying how well adjuvant radiation therapy works in treating patients who have undergone surgery for desmoplastic melanoma.

Condition Intervention Phase
Melanoma (Skin)
Procedure: adjuvant therapy
Radiation: radiation therapy
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Incidence of local recurrence 2 years after completion of study treatment [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Incidence of regional and systemic metastases [ Designated as safety issue: No ]
  • Survival time [ Designated as safety issue: No ]
  • Failure time [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]
  • Fatigue as assessed by the Brief Fatigue Inventory [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: July 2003
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the recurrence rates of patients with desmoplastic melanoma treated with adjuvant radiotherapy after surgical resection.
  • Determine the disease-free and overall survival of patients treated with this regimen.
  • Determine the immediate and long-term morbidity of patients treated with this regimen.

OUTLINE: This is a multicenter study.

Within 8 weeks after surgical resection, patients undergo radiotherapy twice weekly over 2.5 weeks in the absence of unacceptable toxicity.

Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed desmoplastic melanoma

    • Locally recurrent OR at least 1 mm in depth

      • Recurrent tumor is defined as a tumor found no more than 2 cm from the previous excision or within the surgical bed (which includes the extent of previous skin flaps)
  • Disease resected using standard wide resection or Moh's surgery

    • Histologically negative margins
    • Tumors on proximal extremities must have a 2 cm negative margin
    • Tumors on the head or neck or distal extremities may have margins less than 2 cm provided they are negative
  • No melanoma with focally desmoplastic features, in which the desmoplastic melanoma is not the predominant histologic pattern of the tumor
  • No nondesmoplastic neurotropic or nondesmoplastic spindle cell melanoma
  • No evidence of metastatic disease (local nodal disease allowed)



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 1 year


  • Not specified


  • Not specified


  • Not specified


  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other malignancy within the past 5 years except for the following diseases:

    • Basal cell or squamous cell skin cancer
    • Carcinoma in situ of the cervix
    • Stage I breast cancer adequately treated with adjuvant therapy for which the patient is currently disease-free
    • Stage I or II prostate cancer treated with prostatectomy or radiotherapy with a biochemically-free disease status (i.e., for radical retropubic prostatectomy prostate-specific antigen [PSA] < 0.3 and for radiotherapy PSA < 2.0 above the post-treatment nadir)
  • No nonhealing surgical wound
  • No active infection at the surgical site


Biologic therapy

  • No concurrent adjuvant immunotherapy


  • No concurrent adjuvant chemotherapy

Endocrine therapy

  • Not specified


  • No prior radiotherapy to the focused site of this study


  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00060333

  Show 39 Study Locations
Sponsors and Collaborators
North Central Cancer Treatment Group
Study Chair: Barbara A. Pockaj, MD Mayo Clinic Hospital
Investigator: John H. Donohue, MD Mayo Clinic
Investigator: Jan L. Kasperbauer, MD Mayo Clinic
  More Information

Additional Information:
No publications provided

Responsible Party: Jan C. Buckner, North Central Cancer Treatment Group Identifier: NCT00060333     History of Changes
Other Study ID Numbers: CDR0000301633, NCCTG-N0275
Study First Received: May 6, 2003
Last Updated: June 17, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent melanoma
stage I melanoma
stage II melanoma
stage III melanoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas processed this record on July 01, 2015